Contact this trialFirst, we need to learn more about you.
ATR Inhibitor
Ceralasertib + Olaparib/Durvalumab for Gynecological Cancers
Recruiting3 awardsPhase 2
Ottawa, Ontario
This trial is testing a new drug called ceralasertib in patients with relapsed gynaecological cancers. The drug is being tested alone and in combination with other drugs to see how patients
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.